|Other Names||N-myc proto-oncogene protein, Class E basic helix-loop-helix protein 37, bHLHe37, MYCN, BHLHE37, NMYC|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7395b was selected from the C-term region of human MYCN. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Positively regulates the transcription of NCYM in neuroblastoma cells (PubMed:24391509).|
|Tissue Location||Expressed in the neuronal cells of the cerebrum, neuroblastomas and thyroid tumors (at protein level)|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
MYCN is a member of the MYC family and a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH protein in order to bind DNA. Amplification of its gene is associated with a variety of tumors, most notably neuroblastomas.
Combaret,V., Pediatr Blood Cancer 53 (3), 329-331 (2009)Alvarez-Rodriguez,R., J. Cell. Sci. 122 (PT 5), 595-599 (2009)Jacobs,J.F., BMC Cancer 9, 239 (2009)
If you have any additional inquiries please email technical services at email@example.com.